This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?

Biotech giant Eli Lilly (LLY 0.61%) is firing on all cylinders. The company has scorched the broader market over the past year thanks to its rapidly growing revenue and important clinical and regulatory progress. However, the No. 1 reason Eli Lilly has been performing so well is tirzepatide, its clinical compound known as Mounjaro in the diabetes market, and Zepbound in the anti-obesity space.Eli Lilly recently reported more positive news regarding this medicine. Let's find out what it was and what investor ...